Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
NCT04666259
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
56
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
DRUG:
ABL001
Sponsor
Novartis Pharmaceuticals